SynthesisJournal of medicine and life2025
Discoid lupus erythematosus and its progression to systemic lupus erythematosus across age groups: a systematic review.
Synthesis in Journal of medicine and life, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discoid lupus erythematosus (DLE) is a chronic cutaneous form of lupus characterized by erythematous lesions, dyspigmentation, and scarring that may progress to systemic lupus erythematosus (SLE). This systematic review analyzed epidemiology, clinical patterns, immunologic features, progression rates, and treatment outcomes in 2,814 patients across 72 studies, including 626 pediatric/neonatal and 2,188 adult cases. Female participants predominated in both groups (68.5% in pediatrics; 74.2% in adults), with a higher prevalence among African/African American patients (29.6% in pediatrics and 33.8% in adults). The mean age at diagnosis was 11 years in children and 34 years in adults. Localized lesions were most common in pediatric patients (61.3%) and adult patients (58.7%). Progression to SLE occurred in 30.0% of pediatric cases and 25.4% of adults. Identified risk factors included early-onset disease (in children, <10 years; in adults, <20 years), ANA positivity (51% in pediatric; 48% in adult), high ANA titers (≥1:320), and a family history of rheumatic disease. Treatment relied mainly on topical corticosteroids (44.4% pediatric; 51.6% adult) and hydroxychloroquine (11.1% pediatric; 28.7% adult), while newer therapies such as lenalidomide and anifrolumab showed potential benefits. Overall, DLE demonstrates a strong female predominance and a substantial likelihood of progression to SLE, particularly in younger patients with autoantibody positivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.